Evidence map›Paper›PMID 27387598›Full record

ReviewTrends in endocrinology and metabolism: TEM2016

The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis.

Mark A Herman, Varman T Samuel

Open access · greenAbstract readReview
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 3 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Targeting Cryptochromes in Chronic Diseases.Cell biology international · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  20. Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mark A HermanBeth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: mherman1@bidmc.harvard.edu.
Varman T SamuelYale University School of Medicine, 950 Campbell Avenue, West Haven, CT 06516, USA; Veterans Affairs Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA. Electronic address: varman.samuel@yale.edu.
Beth Israel Deaconess Medical Center · USVA Connecticut Healthcare System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Institutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2M
The Role of ChREBP in Fructose Induced Metabolic DiseaseR01DK100425 · NIDDK · DUKE UNIVERSITY · PI HERMAN, MARK A · 2014 to 2023
$3.6M
Cellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.I01BX000901 · VA · VA CONNECTICUT HEALTHCARE SYSTEM · PI SAMUEL, VARMAN T · 2012 to 2020
–
BLRD VA I01 BX000901NCATS NIH HHS KL2 TR001862NCATS NIH HHS UL1 TR001863NIDDK NIH HHS R01 DK100425
6 · The paper itself

Abstract

Epidemiological studies link fructose consumption with metabolic disease, an association attributable in part to fructose-mediated lipogenesis. The mechanisms governing fructose-induced lipogenesis and disease remain debated. Acutely, fructose increases de novo lipogenesis through the efficient and uninhibited action of ketohexokinase and aldolase B which yields substrates for fatty-acid synthesis. Chronic fructose consumption further enhances the capacity for hepatic fructose metabolism by activating several key transcription factors (i.e., SREBP1c and ChREBP) which augment the expression of lipogenic enzymes, increasing lipogenesis and further compounding hypertriglyceridemia and hepatic steatosis. Hepatic insulin resistance develops from diacylglycerol-PKCɛ-mediated impairment of insulin signaling and possibly additional mechanisms. Initiatives that decrease fructose consumption and therapies that block fructose-mediated lipogenesis will be necessary to avert future metabolic pandemics.

Indexed as

AnimalsFructoseHumansInsulinInsulin ResistanceLipid MetabolismLipogenesisSignal TransductionFructoseInsulin

Identifiers

PMID27387598
PMCPMC5035631
OpenAlexW2465210568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.